GSK plc (GLAXF)
| Market Cap | 77.55B |
| Revenue (ttm) | 40.74B |
| Net Income (ttm) | 4.07B |
| Shares Out | n/a |
| EPS (ttm) | 0.98 |
| PE Ratio | 19.04 |
| Forward PE | n/a |
| Dividend | 0.80 (4.26%) |
| Ex-Dividend Date | May 15, 2025 |
| Volume | 750 |
| Average Volume | 8,362 |
| Open | 18.96 |
| Previous Close | 19.02 |
| Day's Range | 18.73 - 18.96 |
| 52-Week Range | 15.54 - 22.45 |
| Beta | 0.27 |
| RSI | 44.25 |
| Earnings Date | Jul 28, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsNews
GSK Strengthens UK Biotech with Major R&D Investment
It was announced on July 3, 2025, that one of the largest UK-based pharmaceutical corporations, known as GlaxoSmithKline (GSK) intends to launch an impressive investment of 500 million pounds to stren...
Price Over Earnings Overview: GSK
In the current session, GSK Inc. (NYSE: GSK) is trading at $38.51, after a 1.13% drop. Over the past month, the stock fell by 5.54% , and in the past year, by 0.77% . With performance like this, long...
'Sad day' as production ends at antibiotic site
GlaxoSmithKline's plant in Ulverston is closing after more than 75 years of operating.
GSK Rebranded Flovent Asthma Inahler For Children To Avoid $367 Million Medicaid Rebate, Senator Hassan Accuses
U.S. Senator Maggie Hassan (D-NH) is intensifying her scrutiny of GSK Plc (NYSE: GSK) over the company's decision to pull its widely used asthma inhaler, Flovent HFA, from the market. One year after ...
US Senator investigates GSK for pulling children's asthma inhaler
Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for chil...
GSK, Bharat Biotech to slash malaria vaccine prices to under $5 per dose by 2028
Bharat Biotech and GSK plc will significantly reduce the price of their malaria vaccine, Mosquirix, to under $5 per dose by 2028. This price cut, exceeding 50%, is part of their commitment to Gavi's r...
Bharat, GSK to halve price of malaria vaccine by 2028
Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to $5 per dose by 2028, more than halving its current cost, they said on Wednesday.
GSK gets FDA nod for Benlysta autoinjector in lupus
FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stim...
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic...
GSK’s RSV vaccine to be reviewed by the EU for expanded use in adults
GSK says EU heath regulator reviewing expansion of RSV vaccine
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to include adults from 18 years of age.
Bharat Biotech in-licences GSK's Shigella vaccine candidate
Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young children in low- and middle-income countries. Following promising early-stage ...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
UW's School of Pharmacy receives $300K investment
The University of Waterloo’s School of Pharmacy announced Friday a partnership with multinational biopharma company GlaxoSmithKline (GSK) that will launch the Pharmacy Innovation in Immunization Resea...
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 ...
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
GSK and Spero ended a Phase 3 trial ... Full story available on Benzinga.com
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for...
GSK, Spero to stop urinary tract infection drug trial due to early success
Spero Therapeutics and partner GSK said on Wednesday that an experimental drug for complicated urinary tract infections met the main goal of a late-stage trial and the companies will be stopping the t...
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually ...
GSK shares break six-session winning streak
GSK wins EU backing for multiple myeloma drug, Blenrep
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult pat...